PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Programmed death ligand 1 (PD-L1) in tumor cells is known to promote immune escape of cancer by interacting with programmed cell death 1 (PD-1) in tumor infiltrating immune cells. Immunotherapy targeting these molecules is emerging as a new strategy for the treatment of glioblastoma (GBM). Understanding the relationship between the PD-L1/PD-1 axis and prognosis in GBM patients may be helpful to predict the effects of immunotherapy. Methods: PD-L1 expression and PD-1–positive tumor infiltrating mononuclear cell (PD-1+tumor infiltrating mononuclear cell [TIMC]) density were evaluated using tissue microarray containing 54 GBM cases by immunohistochemical analysis; the associations with patient clinical outcomes were evaluated. Results: PD-L1 expression and high PD-1+TIMC density were observed in 31.5% and 50% of GBM cases, respectively. High expression of PD-L1 in tumor cells was an independent and significant predictive factor for worse overall survival (OS; hazard ratio, 4.958; p = .007) but was not a significant factor in disease-free survival (DFS). PD-1+TIMC density was not correlated with OS or DFS. When patients were classified based on PD-1 expression and PD-1+TIMC density, patients with PD-L1+/PD-1+TIMC low status had the shortest OS (13 months, p = .009) and DFS (7 months, p = .053). Conclusions: PD-L1 expression in GBM was an independent prognostic factor for poor OS. In addition, combined status of PD-L1 expression and PD-1+TIMC density also predicted patient outcomes, suggesting that the therapeutic role of the PD-1/PD-L1 axis should be considered in the context of GBM immunity.
Abstract
Background: Programmed death ligand 1 (PD-L1) in tumor cells is known to promote immune escape of cancer by interacting with programmed cell death 1 (PD-1) in tumor infiltrating immune cells. Immunotherapy targeting these molecules is emerging as a new strategy for the treatment of glioblastoma (GBM). Understanding the relationship between the PD-L1/PD-1 axis and prognosis in GBM patients may be helpful to predict the effects of immunotherapy. Methods: PD-L1 expression and PD-1–positive tumor infiltrating mononuclear cell (PD-1+tumor infiltrating mononuclear cell [TIMC]) density were evaluated using tissue microarray containing 54 GBM cases by immunohistochemical analysis; the associations with patient clinical outcomes were evaluated. Results: PD-L1 expression and high PD-1+TIMC density were observed in 31.5% and 50% of GBM cases, respectively. High expression of PD-L1 in tumor cells was an independent and significant predictive factor for worse overall survival (OS; hazard ratio, 4.958; p = .007) but was not a significant factor in disease-free survival (DFS). PD-1+TIMC density was not correlated with OS or DFS. When patients were classified based on PD-1 expression and PD-1+TIMC density, patients with PD-L1+/PD-1+TIMC low status had the shortest OS (13 months, p = .009) and DFS (7 months, p = .053). Conclusions: PD-L1 expression in GBM was an independent prognostic factor for poor OS. In addition, combined status of PD-L1 expression and PD-1+TIMC density also predicted patient outcomes, suggesting that the therapeutic role of the PD-1/PD-L1 axis should be considered in the context of GBM immunity.
참고문헌 (35)
- Wen PY, "Malignant gliomas in adults", N Engl J Med, 359, pp.492~507 (2008)
- Weller M, "EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma", Lancet Oncol, 15, pp.e395~e403 (2014)
- Thomas RP, "The incidence and significance of multiple lesions in glioblastoma", J Neurooncol, 112, pp.91~97 (2013)
- Chen DS, "Oncology meets immunology: the cancer-immunity cycle", Immunity, 39, pp.1~10 (2013)
- Ahmadzadeh M, "Tumor antigenspecific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired", Blood, 114, pp.1537~1544 (2009)
- Okazaki T, "PD-1 and PD-1 ligands: from discovery to clinical application", Int Immunol, 19, pp.813~824 (2007)
- Berghoff AS, "Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma", Neuro Oncol, 17, pp.1064~1075 (2015)
- Nduom EK, "PD-L1 expression and prognostic impact in glioblastoma", Neuro Oncol, 18, pp.195~205 (2016)
- Sanmamed MF, "Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation", Cancer J, 20, pp.256~261 (2014)
- Han SJ, "Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion", Neuroreport, 20, pp.1597~1602 (2009)
- Keir ME, "PD-1 and its ligands in tolerance and immunity", Annu Rev Immunol, 26, pp.677~704 (2008)
- Thompson RH, "PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma", Clin Cancer Res, 13, pp.1757~1761 (2007)
- Muenst S, "The presence of programmed death 1 (PD-1)-positive tumorinfiltrating lymphocytes is associated with poor prognosis in human breast cancer", Breast Cancer Res Treat, 139, pp.667~676 (2013)
- Webb JR, "PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer", Cancer Immunol Res, 3, pp.926~935 (2015)
- Taube JM, "Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape", Sci Transl Med, 4, pp.127~137 (2012)
- Teng MW, "Classifying cancers based on T-cell infiltration and PD-L1", Cancer Res, 75, pp.2139~2145 (2015)
- Dudley ME, "Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes", Science, 298, pp.850~854 (2002)
- Louis DN, "WHO classification of tumours of the central nervous system" (2007), IARC Press
- Weber JS, "and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma", J Clin Oncol, 31, pp.4311~4318 (2013)
- Velcheti V, "Programmed death ligand-1 expression in non-small cell lung cancer", Lab Invest, 94, pp.107~116 (2014)
- Droeser RA, "Clinical impact of programmed cell death ligand 1 expression in colorectal cancer", Eur J Cancer, 49, pp.2233~2242 (2013)
- Tokito T, "Predictive relevance of PDL1 expression combined with CD8+ TIL density in stage III nonsmall cell lung cancer patients receiving concurrent chemoradiotherapy", Eur J Cancer, 55, pp.7~14 (2016)
- Zeng J, "Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas", Oncotarget, 7, pp.8944~8955 (2016)
- Hamanishi J, "Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer", Proc Natl Acad Sci U S A, 104, pp.3360~3365 (2007)
- Gao Q, "Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma", Clin Cancer Res, 15, pp.971~979 (2009)
- Wang L, "Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma", World J Surg, 34, pp.1059~1065 (2010)
- Thompson RH, "Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up", Cancer Res, 66, pp.3381~3385 (2006)
- Wang A, "The prognostic value of PD-L1 expression for non-small cell lung cancer patients : a meta-analysis", Eur J Surg Oncol, 41, pp.450~456 (2015)
- Liu YX, "Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia : a meta-analysis", Onco Targets Ther, 9, pp.2649~2654 (2016)
- Razavi SM, "Immune evasion strategies of glioblastoma", Front Surg, 3, pp.11~ (2016)
- Kim MY, "Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma : comparison with tumor-infiltrating T cells and the status of oncogenic drivers", Lung Cancer, 88, pp.24~33 (2015)
- Berghoff AS, "Tumour-infiltrating lymphocytes and expression of programmed death ligand 1(PD-L1)in melanoma brain metastases", Histopathology, 66, pp.289~299 (2015)
- Nduom EK, Weller M, Heimberger AB, "Immunosuppressive mechanisms in glioblastoma", Neuro Oncol, 17(Suppl 7), pp.vii9~vii14 (2015)
- Duchnowska R, "Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1", PD-L axis, 2016, pp.18, 43~
- Harter PN, "Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1", PDL1 immune checkpoints in human brain metastases, 2015, pp.6, 40836~40849